Latest IMPH Community News
NASHVILLE, Tenn. (WTVF) — In a lot of cases, securing a COVID-19 vaccination appointment is like winning the golden ticket. However, for some, the vaccination relief is followed by guilt after getting the shot. "They can feel a little guilty, that’s okay, in time as they realize that they are now insulated to a large degree against a very nasty situation that is developing COVID-19," Dr. Jim Jackson said, "They’re going to feel good, and in time their loved ones are going to get the vaccine."
Vanderbilt University Medical Center has been awarded a one-year, $34-million grant by the National Center for Advancing Translational Sciences, part of the National Institutes of Health, to conduct a nationwide study of “convalescent plasma” as a treatment for COVID-19. The randomized, controlled trial will test whether infusions of plasma, the liquid part of blood collected from COVID-19 survivors, can help other hospitalized patients with COVID-19. The plasma contains antibodies against SARS-CoV-2, the virus that causes COVID-19.
In a new analysis, researchers from the Department of Health Policy at Vanderbilt University School of Medicine and Vanderbilt University Medical Center have found a relationship between the growth of hospitalizations and masking requirements put in place across the state. Hospitals that have more than 75% of their patients from areas without masking requirements in place have seen a relatively faster increase in patients with COVID-19 than hospitals with higher percentages of patients from areas with masking requirements in place.
NASHVILLE, TENN. (WSMV) - A new survey out of Vanderbilt University is showing the toll the coronavirus pandemic is taking on our mental well-being. Researchers polled parents with children under the age of 18 at the beginning of June. They found that 27 percent of parents felt like their own mental health had worsened. 14 percent of those parents saw negative changes in their kids.
Vanderbilt University Medical Center is evaluating razuprotafib, a drug being investigated for the treatment of glaucoma, in a new randomized, investigational trial for the prevention and treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19. “We urgently need to find effective treatments for COVID-19, especially for patients who develop severe lung injury from the virus,” said co-principal investigator Wesley Self, MD, an emergency medicine physician at Vanderbilt University Medical Center.